An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain

European Journal of Pharmacology

Volumn 364, Issue 2-3, 1999, Pages 141-146

  Lynch III, James J ^a   Jarvis, Michael F ^a   Kowaluk, Elizabeth A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Adenosine; Adenosine kinase; Allodynia; Diabetes; Pain; Streptozotocin

Indexed keywords

ADENOSINE KINASE INHIBITOR; MORPHINE; NALOXONE; THEOPHYLLINE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ADENOSINE KINASE; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; MORPHINE; NARCOTICS; PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; THEOPHYLLINE; TUBERCIDIN;

EID: 0032955817     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00840-1     Document Type: Article

References (42)

1. Ahlgren S.C., Levine J.D. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience. 4:1993;1049-1055.
2. Akunne H.C., Soliman K.F.A. The role of opioid receptors in diabetes and hyperglycemia-induced changes in pain threshold in the rat. Psychopharmacology. 93:1987;167-172.
3. Arner S., Meyerson B.A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 33:1988;11-23.
4. Britton D.R., Mikusa J., Lee L., Williams M., Kowaluk E. Adenosine kinase inhibition enhances kainic acid-induced increases in striatal adenosine. Abstr. Soc. Neurosci. 22:1996;1568.
5. Brown M.J., Asbury A.K. Diabetic neuropathy. Ann. Neurol. 15:1984;2-12.
6. Calcutt N.A., Chaplan S.R. Spinal pharmacology of tactile allodynia in diabetic rats. Br. J. Pharmacol. 122:1997;1478-1482.
7. Calcutt N.A., Li L., Yaksh T.L., Malmberg A.B. Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Eur. J. Pharmacol. 285:1995;189-197.
8. Calcutt N.A., Jorge M.C., Yaksh T.L., Chaplan S.R. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain. 68:1996;293-299.
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods. 53:1994;55-63.
10. Clark C.M. Jr., Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N. Engl. J. Med. 332:1995;1210-1217.
11. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain. 53:1993;81-88.
12. Courteix C., Bardin M., Chantelauze C., Lavarenne J., Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain. 57:1994;153-160.
13. Davies L.P., Jamieson D.D., Baird-Lambert J.A., Kazlauska R. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: pharmacological activities and potent inhibition of adenosine kinase. Biochem. Pharmacol. 33:1984;347-355.
14. 2 receptors but have potent pharmacological activity in vivo. Biochem. Pharmacol. 35:1986;3021-3029.
15. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20:1980;441-462.
16. Ellenberg M. Diabetic neuropathy: clinical aspects. Metabolism. 25:1976;1627-1655.
17. Forman L.J., Estilow S., Lewis M., Vasilenko P. Streptozocin diabetes alters immunoreactive beta-endorphin levels and pain perception after 8 wk in female rats. Diabetes. 35:1986;1309-1313.
18. Hounsom L., Tomlinson D.R. Does neuropathy develop in animal models? Clinical Neurosci. 4:1997;380-389.
19. Karlsten R., Post C., Hide I., Daly J.W. The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor. Neurosci. Lett. 121:1991;267-270.
20. Keil G.J. II, DeLander G.E. Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci. 51:1992;171-176.
21. Kowaluk, E.A., Bannon, A., Gunther, K., Kohlhaas, K., Lynch, J., Jarvis, M.F., 1998. Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Pharmacol. Biochem. Behav., in press.
22. Kowaluk E.A., Mikusa J., Wismer C., Jarvis M.F. An adenosine kinase inhibitor attenuates carrageenan-induced hyperalgesia and inflammation in the rat. Drug Dev. Res. 43:1998;148.
23. Lee J.H., McCarty R. Pain threshold in diabetic rats: effects of good versus poor diabetic control. Pain. 50:1992;231-236.
24. Lee Y.-W., Yaksh T.L. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J. Pharmacol. Exp. Ther. 277:1996;1642-1648.
25. Lee Y.-W., Chaplan S.R., Yaksh T.L. Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci. Lett. 199:1995;111-114.
26. Morley G.K., Mooradian A.D., Levine A.S., Morley J.E. Mechanism of pain in diabetic peripheral neuropathy: effect of glucose on pain perception in humans. Am. J. Med. 77:1984;79-82.
27. Poon A., Sawynok J. Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Eur. J. Pharmacol. 286:1995;177-184.
28. Poon A., Sawynok J. Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain. 74:1998;235-245.
29. Portenoy R.K., Foley K.M. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 25:1986;171-186.
30. Post C. Antinociceptive effects in mice after intrathecal injection of 5′-N-ethylcarboxamide adenosine. Neurosci. Lett. 51:1984;325-330.
31. Rakieten N., Rakieten M.L., Nadkarni M.V. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 29:1963;91-98.
32. Rowbotham M.C., Reisner-Keller L.A., Fields H.L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 41:1991;1024-1028.
33. Sawynok J., Reid A., Nance D. Spinal antinociception by adenosine analogs and morphine after intrathecal administration of the neurotoxins capsaicin, 6-hydroxydopamine and 5,7-dihydroxytryptamine. J. Pharmacol. Exp. Ther. 258:1991;370-380.
34. Segerdahl M., Ekblom A., Sjolund K.-F., Belfrage M., Forsberg C., Sollevi A. Systemic adenosine attenuates touch evoked allodynia induced by mustard oil in humans. NeuroReport. 6:1995;753-756.
35. Sollevi A., Belfrage M., Lundeberg T., Segerdahl M., Hansson P. Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain. 61:1995;155-158.
36. Sosnowski M., Yaksh T.L. Role of spinal adenosine receptors in modulating the hyperesthesia produced by spinal glycine receptor antagonism. Anesth. Analg. 69:1989;587-592.
37. Vinik A.I., Holland M.T., LeBeau J.M., Liuzzi F.J., Stansberry K.B., Colen L.B. Diabetic neuropathies. Diabetes Care. 15:1992;1926-1975.
38. Williams, M., Burnstock, G., 1997. Purinergic neurotransmission and neuromodulation: a historical perspective. In: Jacobson, K.A., Jarvis, M.F. (Eds.), Purinergic Approaches in Experimental Therapeutics. Wiley-Liss, New York, NY, pp. 3-26.
39. Wuarin-Bierman L., Zahnd G.R., Kaufmann F., Burcklen L. Adler, hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia. 30:1987;653-658.
40. Yamamoto T., Yaksh T.L. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain. 49:1992;121-128.
41. Zenz M., Strumpf M., Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J. Pain Symptom Manage. 7:1992;69-77.
42. Zhuang H.-X., Snyder C.K., P S.-F., Ishii D.N. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol. 140:1996;198-205.